Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020
20 juil. 2020 06h02 HE
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., July 20, 2020 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio”) (Nasdaq: ASRT), a commercial-stage pharmaceutical company, today announced that its second quarter 2020...
Assertio Therapeutics Announces First-Quarter 2020 Results
11 mai 2020 08h00 HE
|
Assertio Therapeutics, Inc.
-- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5 Million -- -- Repaid Senior Secured Debt in Full and Successfully Tendered for Convertible Debt -- -- Merger...
Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus
20 avr. 2020 17h08 HE
|
Assertio Therapeutics, Inc.
Merger with Zyla Life Sciences Expected to Close Shortly After the 2020 Annual Meeting Assertio Reaffirms its Ability to Achieve Upwards of $40 Million in Synergies Will Report First...
Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024
08 avr. 2020 16h05 HE
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., April 08, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced the completion and final results for its cash tender...
Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products
16 mars 2020 18h45 HE
|
Assertio Therapeutics, Inc.
Combined Company Pro Forma 2019 Net Product Sales of Approximately $128 Million1 Expects to Capture Significant Operating and Product Portfolio Synergies Upwards of $40 Million, Accelerating Revenue...
Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024
11 mars 2020 01h01 HE
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the...
Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results
09 mars 2020 16h02 HE
|
Assertio Therapeutics, Inc.
-- Reports Neurology Franchise Annual Net Sales of $108.1 Million, Exceeding Upper End of Prior Guidance -- -- Completed Strategic Asset Sales of NUCYNTA® Franchise and Gralise® Totaling $502.5...
Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020
02 mars 2020 17h30 HE
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., March 02, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), today announced that it will release fourth quarter and full year 2019...
Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt
19 févr. 2020 08h00 HE
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced it has entered into separate, privately negotiated...
Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million
13 févr. 2020 16h05 HE
|
Assertio Therapeutics, Inc.
LAKE FOREST, Ill., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (“Assertio” or “The Company”) (NASDAQ: ASRT), today announced the closing of its previously disclosed definitive...